Tonix Pharmaceuticals Holding (TNXP) said Thursday it received a patent from the US Patent and Trademark Office for its intranasal migraine treatment, Tosymra.
The patent granted on Tuesday covers the pharmaceutical composition, treatment method, and delivery system for Tosymra, the company said. The patent is set to expire in 2030, excluding potential extensions, it added.
Shares of the company rose over 7% in recent premarket activity.
Price: 0.1565, Change: +0.01, Percent Change: +7.86
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.